CAS 349535-15-5

Chemistry, 1 End Use API, 4 Related Intermediates

Manufacturers/Suppliers

1 Suppliers

1 Suppliers

Also known as: 349535-15-5, 1-(1-methylpiperidin-4-yl)piperazine 3hcl, Cs-0145450, 1-(1-methylpiperidin-4-yl)piperazine;trihydrochloride

Molecular Formula

C₁₀H₂₄Cl₃N₃

Molecular Weight

292.7 g/mol

InChI Key

NDZOOUAUKYVQEO-UHFFFAOYSA-N

1 2D Structure

CAS 349535-15-5

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-(1-methylpiperidin-4-yl)piperazine;trihydrochloride

2.1.2 InChI

InChI=1S/C10H21N3.3ClH/c1-12-6-2-10(3-7-12)13-8-4-11-5-9-13;;;/h10-11H,2-9H2,1H3;3*1H

2.1.3 InChI Key

NDZOOUAUKYVQEO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN1CCC(CC1)N2CCNCC2.Cl.Cl.Cl

2.2 Synonyms

2.2.1 Depositor-Supplied Synonyms

1. 349535-15-5

2. 1-(1-methylpiperidin-4-yl)piperazine 3hcl

3. Cs-0145450

4. 1-(1-methylpiperidin-4-yl)piperazine;trihydrochloride

2.3 Create Date

2013-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₀H₂₄Cl₃N₃
Molecular Weight	292.7 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Exact Mass	g/mol
Monoisotopic Mass	g/mol
Topological Polar Surface Area	18.5
Heavy Atom Count	16
Formal Charge	0
Complexity	146
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	4

List of Suppliers

Full Screen View

Reset Filter

Ask Us

Vamsi Labs

Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

Contact Supplier

India

Virtual Booth

Digital Content

N-Methyl-4- Piperidone

PDF Supplier PDF

URL Supplier Web Content

CAS Number

1445-73-4

End Use API

Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, an...

Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domestic & international markets(50% sales). Anti-asthma products account for 60% of sales. Vamsi adheres to high corporate governance, transparency, professionalism, & environmental protection standards. It's USFDA approved & ISO 9001:2015, ISO 14001:2015, & ISO 45001:2018 certified. With a DSIR-certified R&D Lab, Vamsi continues to innovate & meet the pharma industry's evolving needs. Vamsi is poised to grow its globally while maintaining its commitment to excellence and sustainability.

78th STLE Annual Meeting

Not Confirmed

Contact Supplier

Tagoor Laboratories

Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Contact Supplier

India

Virtual Booth

Digital Content

N-Methyl-4-piperidone

PDF Supplier PDF

URL Supplier Web Content

CAS Number

1445-73-4

End Use API

Zavegepant

About the Company

Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs...

Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-growth therapeutic areas, with an emphasis on affordability, quality and timely delivery. It also provides end-to-end CDMO services. Headquartered in Hyderabad, Tagoor Labs is a fast-growing Indian pharma company that serves both branded and generic companies worldwide. The company’s organizational function includes R&D, supply chain, manufacturing, quality testing, quality assurance, regulatory affairs, marketing & sales, and packaging & warehousing departments.

CPhI China

Booth #E1Q18

envelop Contact Supplier

Porton Pharma Solutions

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

China

Virtual Booth

Digital Content

3-(piperidin-4-yl)quinolin-2(1H)-one hydrochloride

PDF Supplier PDF

URL Supplier Web Content

CAS Number

855778-84-6

End Use API

Zavegepant

About the Company

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzh...

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities are located in China, Slovenia, the US, Belgium, Switzerland, Denmark, with more than 6000 employees worldwide. Porton leads the way with its excellent CDMO services, but also supplies APIs & intermediates for the treatment of critical diseases such as HIV/AIDS, diabetes, cancer, & influenza. Our Process Technology Centers & WHO/USFDA/EMA/PDMA/NMPA-inspected Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets.

ASK
US